Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Hold at Wall Street Zen
Wall Street Zen has upgraded Pulse Biosciences (NASDAQ:PLSE) from a "sell" to a "hold" rating, leading to a consensus "Hold" rating for the stock with an average price target of $30. The company reported mixed Q4 results, beating EPS expectations but missing revenue, while showcasing strong clinical data for its endocardial nPulse catheter. Despite positive clinical updates, recent insider selling activity, including a 20,000-share sale by Kevin Danahy, might be a concern for investors.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences has granted equity inducement awards to two new employees for up to 19,000 shares of common stock, in accordance with Nasdaq Listing Rule 5635(c)(4). These stock options have an exercise price of $4.18 per share and will vest over four years, subject to continued employment. The awards are part of the company's 2017 Inducement Equity Incentive Plan, aiming to attract and retain talent.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. has granted equity inducement awards to two new employees as per Nasdaq Listing Rule 5635(c)(4). These awards, approved on February 18, 2026, consist of options to purchase up to 19,000 shares of common stock at an exercise price of $25.46 per share, vesting over four years. This action is intended to incentivize their employment with the company.
Pulse Biosciences Inc (PLSE) Shares Gap Down to $22.02 on Feb 20
Shares of Pulse Biosciences Inc (PLSE) gapped down by 12.20% to $22.02 on February 20, after reaching an intraday low of $21.70. This price is 16.27% below its 52-week high and 75.32% above its 52-week low. Analysts have an average target price of $26.00 for PLSE, implying an 18.07% upside, and a consensus "Buy" recommendation.
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates
Pulse Biosciences, Inc (PLSE) reported a Q4 loss of $0.26 per share, beating the Zacks Consensus Estimate of a $0.32 loss. The company also surpassed revenue estimates with $0.26 million, compared to zero revenue a year ago. Despite a mixed estimate revisions trend, the stock has gained 85.4% year-to-date and currently holds a Zacks Rank #3 (Hold).
Pulse Biosciences Establishes New $60 Million ATM Program
Pulse Biosciences (PLSE) has announced a new at-the-market (ATM) equity program, allowing the company to sell up to $60 million of its common stock through TD Securities (USA) LLC. This program essentially rolls over existing unused equity capacity, providing the company with flexible funding options without a firm commitment to sell. An analyst rating indicates a Buy with a $30.00 price target, although TipRanks' AI Analyst, Spark, rates the stock as Neutral due to weak financial performance despite some positive developments in trials and early commercial traction.
Pulse Biosciences (NASDAQ:PLSE) Releases Earnings Results, Beats Estimates By $0.06 EPS
Pulse Biosciences (NASDAQ:PLSE) reported adjusted earnings per share (EPS) of ($0.26) for the quarter, exceeding analysts' consensus estimates of ($0.32) by $0.06. Despite beating estimates, shares slipped about 1.5% to $25.08. Insider Kevin Patrick Danahy sold 20,000 shares, though insiders still collectively own 74.60% of the company's stock.
Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q4 Revenue $264K, vs. FactSet Est of $150K
Pulse Biosciences, Inc. (PLSE) announced its Q4 revenue of $264,000, significantly exceeding FactSet's estimate of $150,000. This news was accompanied by other recent updates, including the narrowing of Q4 loss, a plan to offer securities worth $200 million, and a successful atrial fibrillation treatment feasibility study. The company specializes in bioelectric medicine with its CellFX nsPFA technology.
Pulse Biosciences Shares Fall After Q4 Loss Widens as Clinical Spending Rises and Revenue Remains Limited
Pulse Biosciences (PLSE) shares fell after the company reported a widened non-GAAP net loss for both Q4 and full-year 2025, driven by increased clinical spending despite some revenue growth. The company highlighted clinical progress in its cardiovascular and soft tissue ablation programs, including FDA IDE approval for its nPulse Cardiac Catheter System. However, medical device stocks like PLSE are facing investor caution due to higher interest rates and prolonged development timelines, affecting companies in early product adoption stages.
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
Pulse Biosciences announced business updates and financial results for Q4 and full year 2025, highlighting significant advancements in its novel nPulse™ technology for atrial fibrillation and soft tissue ablation. The company achieved FDA approval for a pivotal IDE study for paroxysmal AF treatment and reported increasing revenue and cash balance compared to the previous quarter. Despite a GAAP net loss, Pulse Biosciences emphasized its focus on clinical trial execution and commercialization of its nsPFA platform.
Pulse Biosciences earnings in focus after clinical data surge By Investing.com
Pulse Biosciences Inc. is set to report its Q4 and full-year 2025 earnings, with investors keen to see how the company plans to bridge the gap between strong clinical data and commercial success. Following a significant stock surge earlier this month due to positive clinical results for its nanosecond pulsed field ablation technology, analysts anticipate an EPS loss of $0.33 on $750,000 revenue. Key areas of focus for investors include the timeline for commercialization, the durability of its technology's efficacy against competitors, and the company's funding strategy amidst significant operating losses.
Pulse Biosciences earnings in focus after clinical data surge By Investing.com
Pulse Biosciences Inc. is set to report fourth-quarter and full-year 2025 results amid high investor interest following a significant stock surge earlier in the month due to positive clinical data. Analysts predict a loss of $0.33 per share on $750,000 in revenue, with focus on the company's progress from clinical success to commercial adoption of its nanosecond pulsed field ablation technology. Investors are closely monitoring the timeline for the NANOPULSE-AF study, efficacy durability against competitors, and the company's cash runway and funding strategy.
Pulse Biosciences CCO Danahy sells $1.41 million in stock By Investing.com
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy sold 60,000 shares of company stock for a total of $1.41 million between February 12 and 17, 2026. These sales were executed under a Rule 10b5-1 trading plan. This comes as Pulse Biosciences continues to make significant advancements in its clinical trials for the nPulse Cardiac Catheter System and the nPulse Vybrance Percutaneous Electrode System, garnering positive analyst coverage.
Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock
Kevin Patrick Danahy, an insider at Pulse Biosciences (NASDAQ:PLSE), sold 20,000 shares of the company's stock on February 13th, valued at $470,600. This sale is part of a larger series of transactions between February 9th and 17th, totaling 80,000 shares and approximately $1.88 million, significantly reducing his ownership. Pulse Biosciences shares are trading near $23.67, and analysts currently have a consensus "Hold" rating with an average target price of $26.00.
Pulse Biosciences (NASDAQ:PLSE) Shares Down 9.2% Following Insider Selling
Pulse Biosciences (NASDAQ:PLSE) experienced a 9.2% stock decline after insider Kevin Patrick Danahy sold a total of 40,000 shares in two separate transactions in early February, reducing his stake by 31.6%. Analysts have a mixed view with a consensus "Hold" rating and a $26 target price, although Mizuho set a higher target of $30. The clinical-stage bioelectric medicine firm currently holds a $1.55 billion market cap and high institutional ownership.
PLSE shares positive first-in-human nPulse cardiac catheter data
The article reports that PLSE has released positive initial human trial data for its nPulse cardiac catheter. This suggests a significant step forward in the development of PLSE's medical technology.
Pulse Biosciences (PLSE) Is Up 70.4% After Strong First-in-Human nPulse AF Data Release – Has The Bull Case Changed?
Pulse Biosciences (PLSE) saw a 70.4% increase in stock price following the release of strong first-in-human data for its nPulse Cardiac Catheter in atrial fibrillation treatment. The data highlighted high procedural success, short times, and low adverse events, presented at the 31st Annual AF Symposium. While these results strengthen the investment narrative, investors are still advised to consider the risks associated with trial costs and the company's current low revenue base, alongside the need for larger, longer studies to confirm these early findings.
Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock
Insider Kevin Patrick Danahy sold a total of 40,000 shares of Pulse Biosciences (NASDAQ:PLSE) stock across two transactions in early February, amounting to a value of approximately $933,000. These sales reduced his holdings by 31.60%. The company, a clinical-stage bioelectric medicine firm, remains largely held by institutional investors and recently saw its stock trade up 5.6% on higher volume.
Pulse Biosciences (NASDAQ:PLSE) Insider Kevin Patrick Danahy Sells 20,000 Shares
Pulse Biosciences (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the company's stock on February 11th for $504,000, following an earlier sale of 20,000 shares on February 9th for $429,000. These transactions reduced his total ownership by 31.6% to 43,298 shares. The company’s stock traded up to $25.25, with a market cap of $1.71 billion, while analysts have a mixed "Hold" consensus rating with a $26 average target.
Pulse Biosciences (PLSE) Is Up 70.4% After Strong First-in-Human nPulse AF Data Release – Has The Bull Case Changed?
Pulse Biosciences (PLSE) shares surged 70.4% following the release of strong first-in-human data for its nPulse Cardiac Catheter at the 31st Annual AF Symposium. The data indicated high atrial fibrillation treatment success, short procedure times, and a low rate of serious adverse events. While these early results strengthen the investment narrative, particularly concerning the low adverse event rate and the FDA IDE approval for US clinical trials, investors are advised to consider ongoing trial costs and the company's small current revenue base.
A Look At Pulse Biosciences (PLSE) Valuation After Its Recent Share Price Surge
Pulse Biosciences (PLSE) has seen a significant surge in its share price recently, with a 51.6% one-day return, attracting investor attention. While a popular narrative suggests the stock is 5.7% undervalued with a fair value of $22, based on the potential of its nPulse Vybrance system, an alternative discounted cash flow (DCF) model indicates the market price of $20.75 is significantly ahead of its cash flow value, estimated closer to $2.66. The article encourages investors to consider both perspectives and conduct further research before making investment decisions.
Pulse Biosciences stock hits 52-week high at 22.76 USD By Investing.com
Pulse Biosciences Inc. stock has reached a new 52-week high of $22.76, representing a significant 51.35% surge in one week, despite a negative one-year return. While this indicates strong investor sentiment, InvestingPro analysis suggests the stock is overvalued and not currently profitable, with a high beta and negative EBITDA. The company recently announced positive results from its nPulse Cardiac Catheter System study and FDA approval for a new clinical study, alongside a research collaboration and an Outperform rating from Mizuho.
Abbott details Volt, TactiFlex data; Pulse Biosciences’ results shine
Abbott and Pulse Biosciences presented new clinical data for their atrial fibrillation (AFib) treatment devices at the AF Symposium. Abbott's Volt pulsed field ablation (PFA) system showed an 84.2% freedom from recurrence in paroxysmal AFib and 68% in persistent AFib, while its TactiFlex Duo catheter, for complex cases, achieved an 81% freedom from recurrence in paroxysmal patients. Pulse Biosciences' nPulse cardiac catheter demonstrated 96% procedural success at one year in its first-in-human trial, with minimal adverse effects.
Pulse Biosciences Highlights Strong AF Outcomes From NPulse Feasibility Study
Pulse Biosciences announced strong results from its first-in-human feasibility study of the nPulse Cardiac Catheter System, which uses Nanosecond Pulsed Field Ablation (nsPFA) to treat atrial fibrillation (AF). The study demonstrated high procedural success rates of 100% at six months and 96% at twelve months, along with efficient procedure times and a low rate of serious adverse events. These findings support the system's potential for precise and durable pulmonary vein isolation (PVI), with the company preparing for its pivotal IDE study.
A Look At Pulse Biosciences (PLSE) Valuation After Its Recent Share Price Surge
Pulse Biosciences (PLSE) has seen a significant share price surge, attracting investor attention. While one narrative suggests the stock is 5.7% undervalued with a fair value of $22, another valuation model pegs its fair value much lower at $2.66, indicating it could be expensive. The company's recent commercial traction with its nPulse Vybrance system and anticipated revenue growth are key factors driving the optimistic valuation, despite a reported net loss.
Precision Trading with Pulse Biosciences Inc (PLSE) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Pulse Biosciences Inc (PLSE) with various risk zones and trading strategies based on AI models. It highlights strong near- and mid-term sentiment but a weak long-term outlook, with a breakout currently underway. The report offers specific entry zones, targets, and stop-loss levels for position, momentum breakout, and risk hedging strategies, alongside multi-timeframe signal analysis.
Pulse Biosciences Presents Late-Breaking Data from nPulse Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Pulse Biosciences announced positive late-breaking clinical data from its nPulse Cardiac Catheter first-in-human feasibility study for treating atrial fibrillation (AF). The study showed 100% procedural success at 6 months and 96% at one year, with rapid procedure times and a strong safety profile. This novel nPulse™ technology, using nanosecond Pulsed Field Ablation, aims to revolutionize AF treatment with its efficient workflow and effective, durable results.
Pulse Biosciences Stock Pre-Market (+5.5%): Searching for a Catalyst
Pulse Biosciences stock saw a pre-market increase of 5.5%, indicating investor interest in potential upcoming positive developments. The article suggests that the company is actively seeking a catalyst to drive further growth and improve its market position.
Pulse Biosciences Stock Pre-Market (+5.5%): Searching for a Catalyst
Pulse Biosciences (PLSE) stock is up 5.5% in pre-market trading without an immediate, clear news catalyst, leading to speculation about the cause of the surge. While earlier positive clinical data for its nPulse Cardiac Catheter provided a structural catalyst, today's move is unexplained, possibly driven by speculation, a non-public analyst upgrade, or sector rotation. Traders are advised to watch technical levels and early market volume to determine if the rally will sustain or fade.
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Pulse Biosciences announced positive late-breaking clinical data from its nPulse™ Cardiac Catheter first-in-human feasibility study for atrial fibrillation (AF) treatment. The study, involving 150 patients, demonstrated 100% procedural success at 6 months and 96% at 12 months with rapid procedure times and minimal adverse effects. These results highlight the nPulse system's potential to significantly advance AF treatment, offering a simple, efficient workflow and durable pulmonary vein isolation.
Pulse Biosciences stock rises after positive cardiac catheter study data By Investing.com
Pulse Biosciences (NASDAQ:PLSE) stock surged after presenting positive 6- and 12-month data from its nPulse Cardiac Catheter System feasibility study for atrial fibrillation treatment. The study showed high procedural success rates, rapid procedure times, and a strong safety profile. Analysts view these results as encouraging, with plans for further studies and expansion into Europe and the U.S.
Pulse Biosciences, Inc. Announces nPulse Cardiac Catheter Study Results
Pulse Biosciences, Inc. announced promising results from its nPulse Cardiac Catheter feasibility study on February 5, 2026. The study showed 96% procedural success at one year and 100% at six months, with low average procedure times and a minimal serious adverse event rate. This summary is AI-powered and based on the SEC filing.
Pulse Biosciences (PLSE) Reports Promising Clinical Data from Cardiac Study
Pulse Biosciences (PLSE) has released promising clinical data from its nPulse Cardiac Catheter feasibility study for atrial fibrillation treatment, showing rapid procedure times and minimal adverse reactions across 165 patients. The nPulse Cardiac Catheter Ablation System, utilizing Nano-Pulse Stimulation technology, aims to enhance treatment processes. Despite challenging financial metrics like negative operating margins, the company exhibits strong liquidity and a solid balance sheet, with insider ownership reflecting confidence.
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Pulse Biosciences announced positive late-breaking clinical data from its nPulse™ Cardiac Catheter first-in-human feasibility study for atrial fibrillation (AF) treatment. The study, presented at the AF Symposium, showed 100% and 96% procedural success at 6 and 12 months respectively, with rapid procedure times and minimal adverse effects in 150 patients. The company plans to initiate a pivotal IDE study following these promising results, which suggest the nPulse system could significantly advance AF treatment.
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced it will report its business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will host a conference call at 1:30 PM PT / 4:30 PM ET for investors interested in listening. A live and recorded webcast will also be available on the Pulse Biosciences Investors website.
Maria Sainz Joins Pulse Biosciences Board of Directors
Maria Sainz has been appointed to the Board of Directors of Pulse Biosciences, bringing over three decades of experience in healthcare technology. Sainz has a strong background in guiding medical device companies through various stages of growth and is currently the president and CEO of Hyperfine Inc. Her expertise is expected to be invaluable as Pulse Biosciences advances its innovative nanosecond PFA technology for applications in large clinical markets, including atrial fibrillation.
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced it will report its business updates and financial results for the fourth quarter and full year 2025 on February 19, 2026, after market close. The company's management will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day to discuss the results. Investors can access the call via phone or webcast.
Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
Pulse Biosciences announced that its nPulse Cardiac Catheter, using proprietary Nanosecond Pulsed Field Ablation (nsPFA) energy, will be prominently featured at the 31st Annual AF Symposium 2026. This includes a late-breaking clinical science session presenting positive 6-month and 12-month follow-up data from a European human feasibility study, and a live case transmission demonstrating the catheter's integration with Abbott’s EnSiteX™ 3D Mapping System. The presentations aim to highlight the disruptive potential of nPulse technology for treating atrial fibrillation.
Pulse Biosciences' nPulse Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
Pulse Biosciences announced that its nPulse Cardiac Catheter, utilizing Nanosecond Pulsed Field Ablation (nsPFA) technology, will be featured in multiple presentations at the 31st Annual AF Symposium 2026. This includes a late-breaking clinical science session detailing 6- and 12-month follow-up data from its European Human Feasibility Study and a live case transmission showcasing the catheter's integration with Abbott's EnSiteX™ 3D Mapping System. The presentations will highlight the nPulse technology's disruptive potential for treating atrial fibrillation, with data showing significantly deeper cardiac lesions from nanosecond pulses compared to microsecond pulses.
Mizuho initiates Pulse Biosciences stock with Outperform rating, $25 target By Investing.com
Mizuho has initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with an Outperform rating and a $25 price target, citing strong physician feedback on its nsPFA technology and potential for shares to re-rate higher based on upcoming EU early feasibility data. Despite current unprofitability, the company maintains a strong liquidity position, and recent developments include FDA approval for a clinical study on atrial fibrillation and collaboration on thyroid cancer treatment.
Mizuho Securities Initiates Coverage on Pulse Biosciences With Outperform Rating
Mizuho Securities has initiated coverage on Pulse Biosciences (PLSE) with an Outperform rating. The company, a bioelectric medicine firm, focuses on its proprietary CellFX nsPFA technology for medical applications, including atrial fibrillation treatment. Following this news, Pulse Biosciences' stock showed a 0.70% increase in early trading.
Mizuho initiates Pulse Biosciences stock with Outperform rating, $25 target By Investing.com
Mizuho initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with an Outperform rating and a $25 price target, citing positive physician feedback on its nanosecond PFA technology. The firm anticipates shares to re-rate higher based on upcoming 12-month EU feasibility data and sees potential for 75% upside from its current trading price. The $25 price target is based on a risk-adjusted sum-of-the-parts analysis for its PFA technology and remaining portfolio, despite the company not yet being profitable.
Technical Reactions to PLSE Trends in Macro Strategies
This article analyzes Pulse Biosciences Inc (PLSE) using AI models, identifying a positive near-term sentiment with a broader weak alignment and a mid-channel oscillation pattern. It highlights exceptional short setup risk-reward, divergent sentiment across horizons, and provides various trading strategies tailored to different risk profiles and holding periods, including position, momentum, and risk-hedging strategies. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring A 53% Upside Potential
Pulse Biosciences (NASDAQ: PLSE) is a bioelectric medicine company developing the CellFX System for various medical conditions using nanosecond pulsed-field ablation (nsPFA) technology. Despite a recent stock dip to $14.32, analysts project a 53.63% upside to an average target price of $22.00, driven by its innovative technology and growth prospects. While the company reinvests heavily in R&D, indicated by negative EPS and ROE, its focus on non-invasive treatments and strategic expansion make it a potential long-term growth opportunity for investors.
Trading the Move, Not the Narrative: (PLSE) Edition
This article analyzes Pulse Biosciences Inc (PLSE) using AI models to provide trading strategies. It highlights weak sentiment in the near-term and long-term, resistance testing, and an exceptional risk-reward short setup. The piece offers different trading strategies tailored for various risk profiles and holding periods, alongside multi-timeframe signal analysis.
Pulse Biosciences, Inc. Updates Investor Presentation
Pulse Biosciences, Inc. (PLSE) announced an updated investor presentation on January 14, 2025, detailing progress in product development. Key highlights include new information on their nPulse Vybrance Percutaneous Electrode and updates on their nPulse Cardiac Clamp and Catheter. The full investor deck is available on the company website.
Pulse Biosciences Nabs FDA IDE Approval for nPulse Cardiac Catheter Ablation System Study
Pulse Biosciences has received FDA Investigational Device Exemption (IDE) approval for its nPulse Cardiac Catheter Ablation System Study (NANOPULSE-AF) to treat paroxysmal atrial fibrillation (PAF). The study will enroll up to 145 patients across 30 sites, aiming to demonstrate the safety and effectiveness of their proprietary nanosecond Pulsed Field Ablation (nsPFA) technology. This technology offers a potentially safer and more efficient approach than existing methods, using lower total energy to reduce collateral injury and simplify the ablation procedure.
Pulse Biosciences updates investor deck on cardiac pipeline
Pulse Biosciences (PLSE) has updated its investor presentation to showcase progress in its nPulse cardiac devices, including the Vybrance Percutaneous Electrode, Cardiac Clamp, and Cardiac Catheter. The company aims to provide stakeholders with a consolidated view of its development trajectory for these cardiac-focused technologies. Spark, TipRanks’ AI Analyst, rates PLSE as Neutral due to weak financial performance but notes technical indicators suggesting near-term stabilization and clinical/regulatory progress.
New Cardiac Ablation Data and Board Appointment Might Change The Case For Investing In Pulse Biosciences (PLSE)
Pulse Biosciences recently appointed Maria Sainz to its Board of Directors and announced upcoming data presentations for its nPulse Cardiac Catheter Ablation System. This leadership addition and early clinical data are expected to significantly influence the perception of Pulse Biosciences' long-term potential in the cardiac ablation market, amidst its current small revenue and ongoing losses. The company's investment narrative hinges on its nanosecond pulsed field ablation platform transitioning to a scalable commercial cardiac franchise.
New Cardiac Ablation Data and Board Appointment Might Change The Case For Investing In Pulse Biosciences (PLSE)
Pulse Biosciences (PLSE) recently appointed Maria Sainz to its Board of Directors and will present new cardiac ablation data at the 2026 AF Symposium. This combination of experienced leadership and promising clinical data for its nPulse Cardiac Catheter Ablation System could significantly influence investor perception and the company's long-term potential. While acknowledging current low revenue and losses, these developments are presented as crucial for the company's investment narrative, particularly its potential to commercialize its nanosecond pulsed field ablation platform.
